Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

Why did Tesla shares fall after Musk's new party announcement? How will Trump's new tariffs affect Japan and South Korea? What impact will Meta hiring Apple's AI exec have? Why is CoreWeave acquiring Core Scientific for $9 billion? How are Amazon and Walmart competing during Prime Day? What caused Samsung’s large Q2 profit decline? Why are German companies planning major investments now?

Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

finance.yahoo.com/news/teva-ajovy-shows-sustained-long-093205864.html

In This Article:
Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts. On June 24, Teva Pharmaceutical announced the final analysis results from its PEARL Phase IV migraine prevention trial for Ajovy (fremanezumab), which is an…

This story appeared on finance.yahoo.com, 2025-07-08 09:32:05.